Esophageal motility

M (Brian) Fennerty, Harinder S. Garewal

Research output: Contribution to journalArticle

Abstract

Nitric oxide, the nonandrenergic, noncholingergic neurotransmitter, appears to be the inhibitory neurotransmitter that effects lower esophageal sphincter relaxation. Perturbations in this neurotransmitter axis may be responsible for diseases associated with lower esophageal sphincter dysfunction leg, gastroesophageal reflux disease, achalasia). It is likely that efforts directed at correcting the perturbation in nitric oxide effect will result in novel treatments for these diseases. As increasing options for treatment of achalasia become available, the optimal approach to therapy may finally be realized. Appropriate economic models will need to be developed, because it is unlikely that long-term controlled clinical trials comparing surgical therapy with endoscopic or pharmacologic therapy will be performed. Finally, dysfunction of the upper esophageal sphincter is being increasingly recognized; however, appropriate evaluation, treatment, and natural history of these disorders are as yet unknown.

Original languageEnglish (US)
Pages (from-to)373-379
Number of pages7
JournalCurrent Opinion in Gastroenterology
Volume12
Issue number4
StatePublished - 1996

Fingerprint

Neurotransmitter Agents
Lower Esophageal Sphincter
Esophageal Achalasia
Nitric Oxide
Upper Esophageal Sphincter
Economic Models
Controlled Clinical Trials
Gastroesophageal Reflux
Natural History
Leg
Therapeutics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Fennerty, M. B., & Garewal, H. S. (1996). Esophageal motility. Current Opinion in Gastroenterology, 12(4), 373-379.

Esophageal motility. / Fennerty, M (Brian); Garewal, Harinder S.

In: Current Opinion in Gastroenterology, Vol. 12, No. 4, 1996, p. 373-379.

Research output: Contribution to journalArticle

Fennerty, MB & Garewal, HS 1996, 'Esophageal motility', Current Opinion in Gastroenterology, vol. 12, no. 4, pp. 373-379.
Fennerty, M (Brian) ; Garewal, Harinder S. / Esophageal motility. In: Current Opinion in Gastroenterology. 1996 ; Vol. 12, No. 4. pp. 373-379.
@article{30e4c39478ca461f8e8154044d025a26,
title = "Esophageal motility",
abstract = "Nitric oxide, the nonandrenergic, noncholingergic neurotransmitter, appears to be the inhibitory neurotransmitter that effects lower esophageal sphincter relaxation. Perturbations in this neurotransmitter axis may be responsible for diseases associated with lower esophageal sphincter dysfunction leg, gastroesophageal reflux disease, achalasia). It is likely that efforts directed at correcting the perturbation in nitric oxide effect will result in novel treatments for these diseases. As increasing options for treatment of achalasia become available, the optimal approach to therapy may finally be realized. Appropriate economic models will need to be developed, because it is unlikely that long-term controlled clinical trials comparing surgical therapy with endoscopic or pharmacologic therapy will be performed. Finally, dysfunction of the upper esophageal sphincter is being increasingly recognized; however, appropriate evaluation, treatment, and natural history of these disorders are as yet unknown.",
author = "Fennerty, {M (Brian)} and Garewal, {Harinder S.}",
year = "1996",
language = "English (US)",
volume = "12",
pages = "373--379",
journal = "Current Opinion in Gastroenterology",
issn = "0267-1379",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Esophageal motility

AU - Fennerty, M (Brian)

AU - Garewal, Harinder S.

PY - 1996

Y1 - 1996

N2 - Nitric oxide, the nonandrenergic, noncholingergic neurotransmitter, appears to be the inhibitory neurotransmitter that effects lower esophageal sphincter relaxation. Perturbations in this neurotransmitter axis may be responsible for diseases associated with lower esophageal sphincter dysfunction leg, gastroesophageal reflux disease, achalasia). It is likely that efforts directed at correcting the perturbation in nitric oxide effect will result in novel treatments for these diseases. As increasing options for treatment of achalasia become available, the optimal approach to therapy may finally be realized. Appropriate economic models will need to be developed, because it is unlikely that long-term controlled clinical trials comparing surgical therapy with endoscopic or pharmacologic therapy will be performed. Finally, dysfunction of the upper esophageal sphincter is being increasingly recognized; however, appropriate evaluation, treatment, and natural history of these disorders are as yet unknown.

AB - Nitric oxide, the nonandrenergic, noncholingergic neurotransmitter, appears to be the inhibitory neurotransmitter that effects lower esophageal sphincter relaxation. Perturbations in this neurotransmitter axis may be responsible for diseases associated with lower esophageal sphincter dysfunction leg, gastroesophageal reflux disease, achalasia). It is likely that efforts directed at correcting the perturbation in nitric oxide effect will result in novel treatments for these diseases. As increasing options for treatment of achalasia become available, the optimal approach to therapy may finally be realized. Appropriate economic models will need to be developed, because it is unlikely that long-term controlled clinical trials comparing surgical therapy with endoscopic or pharmacologic therapy will be performed. Finally, dysfunction of the upper esophageal sphincter is being increasingly recognized; however, appropriate evaluation, treatment, and natural history of these disorders are as yet unknown.

UR - http://www.scopus.com/inward/record.url?scp=0029838451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029838451&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 373

EP - 379

JO - Current Opinion in Gastroenterology

JF - Current Opinion in Gastroenterology

SN - 0267-1379

IS - 4

ER -